Taken together, we demonstrated that LEO improves oxidative stress and vascular remodeling induced by obesity and targets YTHDF1, raising the possibility of LEO treating other obesity-related metabolic syndromes. Here, YTHDF1 is linked to obesity due to melanocortin 4 receptor deficiency.